Recruitment - Articles

Clinical Professionals offers clients a unique ‘suite’ of candidate attraction tools that are proven to be invaluable to employers in the highly competitive clinical recruitment market with a specialist headhunting team, which proactively searches for the rarest talent in the marketplace on an ongoing basis.
Clinical Professionals Limited is an innovative company addressing clinical research in a unique fashion.  Our management team incorporates industry experience, in-depth clinical knowledge coupled with over 10 years pharmaceutical recruitment expertise to focus on attracting the highest calibre clinical research professionals to selected opportunities within the pharmaceutical industry. We will always work ethically, and consultatively to ensure that the service is customer focused…

Data presented at the American Society of Clinical Oncology (ASCO) meeting in Atlanta this month suggest that administering the epidermal growth factor receptor (EGFR) inhibitor Erbitux (cetuximab) fortnightly rather than weekly in metastatic colorectal cancer (mCRC) is a feasible option. Another study probing whether scaling up the dose, to the point where patients experience the significant rash linked to long survival, achieves a better response, shows high doses are well tolerated.
Administering treatment in community oncology units achieves results that match those of specialist centres, according to the MABEL study; and phase III trials in the US and Europe are now focusing on investigating Erbitux as a first-line therapy option for mCRC.  Fortnightly regimen could make life eas…

Osteoarthritis is the leading cause of disability in the US, and is estimated to be the eighth most common cause of disability worldwide, with around 89 million adults in the seven major markets having a form of symptomatic osteoarthritis. OA therefore offers an attractive commercial target. However, relatively low disease awareness and Cox-2s controversy have curbed the market's potential so far.
Osteoarthritis (OA) is a degeneration of the joints characterized by progressive destruction of articular cartilage and articular structures. It is a complex process that involves multiple changes in joint structure and, according to Datamonitor estimates, affects 89 million adults in the seven major pharmaceutical markets. Due to the current widespread nature of the condition, the World Health…

Psychiatrists attending this year’s Annual Psychiatric Association meeting heard new findings from the controversial CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) programme. New data suggest an older typical antipsychotic drug is more cost effective and has the same cognitive benefits as newer atypical drugs. Previous results suggested the older first generation drug is equally effective and well-tolerated clinically, compared to newer atypicals but the study design was m
In December 2005, the New England Journal of Medicine published the first results of the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) (1).  The 18-month, double-blind study, funded by the US National Institute of Mental Health (NIMH), compared an older and much cheaper ty…

Colin Williams, e-Marketing Director at PharmiWeb Solutions takes a look at the current e-detailing landscape and suggests what the future could hold for this much talked about tool for pharmaceutical sales and marketing departments.
Introduction - e-detailing, eDetailing, e-detail, eDetail, v-Detail, online detail…. Whatever you call it, there has been no escaping it over the past few years and with more people than ever who are connected with the pharmaceutical industry talking about it, this is only set to get worse…or better in my opinion! I’ve been involved in e-detailing since the heady dotcom days of 2000 and have been providing solutions for the pharmaceutical industry since then. While my frustrations with how long it has taken the industry to take full advantage of e-detailing hav…

DailyUpdates 19th May, 2006: Today's edition of DailyUpdates (see it in full here) carries a couple of important articles on renal disease. One loks at the outcome of patients with renal dysfunction across various acute coronary syndromes. The featured article however demonstrates the efficacy of Novartis' Benazepril in treating advanced renal disease
DailyUpdates 19th May, 2006: Today's edition of DailyUpdates (see it in full here) carries a couple of important articles on renal disease. One loks at the outcome of patients with renal dysfunction across various acute coronary syndromes. The featured article however demonstrates the efficacy of Novartis' Benazepril in treating advanced renal diseaseBenazepril offers hope to patients with advance renal disease - Angiotensin-converting-enzym…

Without treatment, an estimated one in three women will experience an osteoporosis-related fracture during their lifetime
Without treatment, an estimated one in three women will experience an osteoporosis-related fracture during their lifetime (1). The risk of fracture can be substantially reduced by oral nitrogen-containing bisphosphonates such as alendronate (Fosamax) and risedronate (Actonel).  However, although these are widely prescribed, they are not widely adhered to by patients. At least half to three quarters of women stop treatment within one year (2).  Reasons for poor adherence are generally ascribed to inconvenience and, in part, to upper gastro-intestinal (GI) side effects which are thought to affect around one in five.  Dosing is complicated. Tablets have to…

When not doing 'insane sports', Amgen's Europe chief Rolf Hoffmann is battling big pharma
At Amgen, the world's largest biotechnology company, health is not just the way people make their money. It is also a serious business in employees' personal lives. The California-based company has America's largest cycling club and if you want to get into the gym at lunchtime but have not booked a spot on the treadmill, forget about it. Even by this company's energetic standards, Rolf Hoffmann, head of Amgen's international operations, takes his exercise more seriously than most. A former Olympic swimmer for Germany, Mr Hoffmann is a self-confessed addict to "iron-man and insane, long-distance events". This summer, the 47-year-old will compete in a 200 mile race across Switzerland - one of Amgen'…

This summit aims to provide both strategic and practical information that will ensure that organisations can prepare for and survive what is now considered to be the inevitable pandemic. Professor Hugh Pennington from the Department of Medical Microbiology at University of Aberdeen will repeat his warning that, “Only one thing is certain and that is that there will be a pandemic.”
The topics to be covered at the Summit will stress that comprehensive plans must cover seemingly diverse aspects such as legal policy, staff travel, quarantine arrangements, as well as controlling rumour, speculation and scaremongering that can easily rage out of control If you or your team wish to attend , you can email me or register through one of the options below. You can view the programme and…

A new report estimates that there will be approximately 84,000 cases of adult and childhood leukemia in the world's seven major pharmaceutical markets in 2006. Acute leukemias will account for 43% of these cases, and, although this market is relatively small compared to other cancer types, the clear unmet needs and regulatory incentives should help encourage drug makers.
Rlapse rates high Unfortunately, relapse rates following treatment for AML and ALL are high, and current treatments offer little chance of long-term survival for most patients. While developmental drugs in this area have the opportunity to garner orphan drug designation and fast track approval status by the FDA, given the niche nature of treatments for this form of cancer, the return on investment for developers of novel…

This Conference will provide a platform for intellectual discourse in order to answer these questions and to discuss other pressing issues regarding the pharmaceutical industry in China in particular, and the world in general. Opportunities and challenges within the whole value chain, from research and development down to sales and marketing will be discussed and solutions put forward for the benefits of attendees.
WHAT YOU WILL TAKE AWAY FROM THIS CONFERENCE We believe that the quality of a conference program comes from listening to the requests and advice given by our target market. We pride ourselves in providing the most-up-to date subject matter suggested by the market in an environment that is conducive to networking and learning. At this event, you will have the unique opportunity…

This month we try to unravel the mystery (or some may say misery) of assessment centres and interview techniques. As the job market becomes more competitive companies are tending to conduct assessment centres for job placement and also for development purposes.
These assessments may involve psychometric tests. Many of us may have experienced assessment centres when applying for new positions however there are few people who attend these centres who really enjoy them. For some the assessment centre can be a barrier for them in applying for a new job. Psychometric and personality tests are often the tests that people are most wary of as employees outside of HR do not generally understand why they are used. If you want to understand more about assessment centres and how psychometric tests w…

I recently ran a quick poll on PharmiWeb, to determine what level of awareness there was for RSS (really simple syndication). So...
According to our quick RSS survey, 68% of respondents had no idea what it was or how to use it. This is a shame as we, and many other sites in the pharmaceutical industry are  providing them.So lets start with "what is RSS?" - essentially its a data standard that allows data to be made available in a format that can be easily picked up by a simple reader you install on your computer. In reality there are several standards, but most reader software reads them all. What this means to you is that by installing a small piece of software, you can elect to collect news (or whatever information sites make available) from across the web, and collect them into a si…

Why ? Decision makers were not aware of the ROI that can have a search engine marketing strategy.
Over the last 8 years, Pharmaceutical companies and groups did not consider any move that attracts and recruit leads in the best cost effective way. Why ? Decision makers were not aware of the ROI that can have a search engine marketing strategy. elias KAI www.Google-kai.com

The 2nd international exhibition and conference event focussed exclusively on the theme of outsourcing in the research and development of new medicines. Companies both large and small are adopting this increasingly popular business strategy.
The 2nd international exhibition and conference event focussed exclusively on the theme of outsourcing in the research and development of new medicines. Companies both large and small are adopting this increasingly popular business strategy.  Pabord is relevant to service providers and R&D organisations active across the entire discovery and development chain from lead generation to product registration

Your cv is one of the most important documents you will ever write, particularly in the new internet era of recruitment. With job application becoming easier it follows that more applications are goin
Your CV is one of the most important documents you will ever write, particularly in the new internet era of recruitment. With job application becoming easier it follows that more applications are going to be received for each position advertised and this places even more emphasis on the recruiter to filter all of these applications. As a result many recruiters employ blanket rules in the first stage of whittling down the number of applicants for a post until they are in a position to invite people for interview. It is here where the most minor things can let you down, simple spelling mistakes,…

If Sales Force Effectiveness is high on your agenda in the current climate, then don’t miss Pharma IQ’s Next Generation Pharmaceutical Sales Strategies event in June. Learn from speakers who have effectively increased their sales force ROI & successfully implemented alternative options to drive sales effectiveness.
If Sales Force Effectiveness is high on your agenda in the current climate, then don’t miss Pharma IQ’s Next Generation Pharmaceutical Sales Strategies event in June.  Learn from speakers who have effectively increased their sales force ROI & successfully implemented alternative options to drive sales effectiveness.  Why should you attend this event?  Including real industry case studies from Pfizer, Novartis, Orion Pharma, Takeda UK, Chiesi Farmaceutic…

Back in 2000, I was really, really excited. Had I got a date with Kylie Minogue? No. Had West Ham won the Champions League? Not likely. I was excited because I thought I had discovered the best investment sector in the market -- life sciences.
Back in 2000, I was really, really excited. Had I got a date with Kylie Minogue? No. Had West Ham won the Champions League? Not likely. I was excited because I thought I had discovered the best investment sector in the market -- life sciences. How could I lose? The potential of new technologies such as genomics and monoclonal antibodies appeared to be huge. On top of that, I knew that most people in the developed world were living longer and becoming richer too. Buying shares in drugs companies was close to a sure thing! As time went on, I began…

PharmiWeb recently asked Merck to provide some insight into what it was like to work as a sales rep for their company. Rather than just telling us what they thought we wanted to hear, they took the more open approach of asking their team for "real life" comments, and then gave us their rather impressive raw responses, with no additions or changes.
1. OPPORTUNITIES The small size of the company means that everyone is recognised as a person who plays a vital role in the success of their territory and region, and individual successes, however small, are noted. Merck is also constantly giving me opportunities to progress within the company.We have an excellent portfolio, products that save lives and that I genuinely believe in.Autonomy and recognition for sales successes.Supportive managers, w…

ICON’s core competency is project management, built up over the last fifteen years managing complex projects and underpinned by comprehensive and consistent processes which conform to the ISO9001:2000 quality certification.
1. Can you describe ICON for me in a single sentence? ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries.2. How and when did ICON start? ICON was founded in 1990 by Dr. John Climax and Dr. Ronan Lambe. Originally launched with just five staff all based in Dublin, we grew organically for our first 10 years, making our first acquisition in 2000. We now have 3000 staff operating from 41 offices across 27 countries. 3. Why do you think ICON is so successful?The quality of our peop…